Cancer

Oncology, dermatology, hematology pace Q1 biopharma licensing

During the first quarter of 2019, Cortellis Deals Intelligence registered 1,023 new deals (excluding mergers & acquisitions) as part of its ongoing coverage of licensing activity in the life sciences sector, a minor decrease of 0.6% from 1,029 in Q1 a year ago. The total disclosed deal value rose to $44.9 billion, a 26.8% rise […]

FDA draft guidance addresses inclusion of adolescents in oncology trials

With an eye toward helping industry, investigators and institutional review boards (IRBs), the U.S. Food and Drug Administration (FDA) has unveiled draft guidance on the inclusion of adolescents—defined as those between the ages of 12 and 17—in adult oncology trials. Allowing adolescents in relevant trials would allow for earlier access to life-saving drugs in this […]

ASCO 2018: paradigm changers and emerging blockbusters

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered both onsite at ASCO and from Clarivate Analytics Cortellis. The American Society for Clinical Oncology […]

ESMO session explores CDK inhibition and cell cycle modulation in cancer

The principles of CDKs/cyclins in cell-cycle progression Deregulation of the cell cycle is a common feature of human cancer. The mammalian cell cycle is controlled by a subfamily of cyclin-dependent kinases (CDKs), the activity of which is modulated by several activators (cyclins) and inhibitors (INK4, and WAF1/KIP inhibitors). The activity of cell cycle CDKs is […]

Accelerating – and maintaining – drug approvals in the U.S.

Bringing a drug to market is the ultimate milestone for any pharmaceutical firm that has invested significant effort, not to mention time and resources, into developing its product. But all that work and outlay does not stop at marketing approval—this achievement must be maintained. There can be various regulatory requirements that a firm must meet […]

Checkpoint inhibitors: a cutting edge in oncology

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.

NGS, maybe, sort of, sometimes clinic ready

Detailed genomic profiling is a sine qua non of precision medicine, and at tertiary cancer centers, the comprehensive profiling of tumors and matched germline DNA is becoming ever more routine.

The 3 Rs of cancer research: rigor, reproducibility and robustness

As scientists gathered at the 2017 meeting of the American Association for Cancer Research (AACR) in Washington in early April to learn about the latest advances in cancer research, one of the questions was how much of that research would hold up to attempts to reproduce it.